New pill could help hepatitis b patients who Don't respond to standard care

NCT ID NCT07090759

Recruiting now Disease control Sponsor: Fujian Akeylink Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental drug or a placebo, alongside their usual medication. The main goal is to see if the virus levels become undetectable during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GST-HG141 (Neracorvir) – an experimental drug taken as a pill
What this could lead to: If successful, this could offer a new combination treatment option for people with chronic hepatitis B who don't respond well enough to current antiviral drugs.
What could go wrong: This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shulan(Hangzhou) Hospital
RECRUITING

Hangzhou, Zhejiang, 310011, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.